It is reported that the special collection of insulin produced a successful result last year 1 1 month. In the first year of centralized purchasing, the purchase demand was 2. 1 100 million pieces, involving an amount of17 billion pieces. The average price of the selected products dropped by 48%, with the highest drop of 73%. It is estimated that the annual cost of insulin can be saved about 9 billion yuan after centralized collection, which will further reduce the drug burden for more than10 million patients who need long-term or even lifelong insulin injection.
The price of the selected products in insulin centralized purchase is the payment standard, and the medical insurance fund pays according to the prescribed proportion. Non-selected insulin products belong to the scope of medical insurance fund payment, and the payment standard does not exceed the highest selected price of products in the same category or the negotiated price of medical insurance. Patients use non-selected products, and the part whose price exceeds the medical insurance payment standard is paid by the patients themselves. All localities should make overall plans to balance the setting of online prices, the proportion of patients paying and the payment standard of medical insurance, and strive to reduce the burden of patients' expenses.
Insulin is a commonly used drug to treat diabetes. Since May this year, the selected varieties of the national drug centralized procurement of insulin have been implemented in various places, with an average price reduction of 48%.
Wu Jianjun, a diabetic patient in Hunan, comes to the endocrinology department of Hunan Provincial People's Hospital every month to inject long-acting insulin. Since May 3rd1day, Wu Jianjun has felt the obvious change in price.
Patient Wu Jianjun: In the past, each cigarette cost more than RMB 190, and it cost about three cigarettes a month. Now, each cigarette only costs 79.
It not only reduces the burden on patients, but also improves the continuity of drug use for patients, which is very beneficial to control the development of the disease. At present, the number of people with diabetes in China is10.40 billion, and more than10 million patients need long-term or even lifelong insulin injection. This time, 32,000 medical institutions participated in the reporting of insulin demand. In the first year, the purchasing demand was 2. 1 billion, involving an amount of17 billion. It is estimated that the annual cost of insulin can be saved by about 9 billion yuan after the collection.
If you want to know more financial news in real time, please follow us.